Proposed tariffs on medical technology imports put as many as 3 million existing American jobs at risk, according to an analysis published by the Washington Examiner — a figure that sits uncomfortably beside the Trump administration's stated goal of creating more US employment. The headline number is stark. The medtech sector directly and indirectly supports roughly 3 million jobs across the United States, and the industry's supply chains remain deeply dependent on imported components, raw materials and finished devices. Tariff measures designed to push manufacturing onshore would, in the near term, raise input costs for the very companies employing those workers. For shippers and forwarders handling medical technology cargo, the commercial consequences are direct. Tariff regimes on medical devices and components would raise landed costs on trade lanes serving US importers, compressing margins for distributors and likely shifting sourcing decisions toward tariff-exempt or lower-duty origins. Freight volumes on transpacific and transatlantic medtech lanes would feel the effect as buyers reroute procurement. Carriers, for their part, would face a familiar pattern: tariff-driven demand volatility on lanes where medical equipment and pharmaceutical inputs make up a meaningful share of containerized and air cargo. Medtech moves heavily by air, and any redistribution of sourcing away from China or the EU toward domestic production or third countries would reshape airfreight flows before it reshapes container flows. The Washington Examiner's core argument is straightforward: the policy math does not add up. The administration frames tariffs as a lever to repatriate manufacturing jobs, but the medtech example shows the opposite risk — imposing new costs on an industry that already employs millions domestically. Reshoring a complex, regulated supply chain in medical devices takes years of capital investment, facility construction and FDA-compliant qualification. In the interim, tariffs function as a tax on existing operations rather than an incentive that can be acted on quickly. That dynamic matters for the logistics sector because medtech supply chains are among the most exacting in freight. Temperature-controlled airfreight, validated packaging, serialized tracking and tight regulatory documentation define the mode. Any cost shock at the border propagates through the chain — from importer of record to customs broker to the forwarder managing the lane. For US hospitals and healthcare providers, higher device costs carry a second-order effect: procurement budgets strained by tariffs leave less room for other spending, and device makers under margin pressure may consolidate distribution networks, cutting the number of suppliers and shipping nodes. The industry has argued in past tariff rounds that medical devices should be exempted on public-health grounds, and previous administrations have at times granted exclusions for medically necessary products. Whether the current round of measures carves out medtech remains the pivotal question for importers planning volumes and for carriers assessing lane exposure. What is clear from the Washington Examiner analysis is the tension at the heart of the policy: 3 million jobs already anchored in the US medtech economy depend on import-reliant supply chains, and tariff escalation puts those positions in jeopardy long before any reshored production capacity comes online. Shippers, forwarders and carriers with medtech exposure should watch the exemption process closely — the trajectory of exclusions and duty rates will determine both landed costs and lane volumes for quarters to come.